BlackRock Inc. Purchases New Shares in TuHURA Biosciences, Inc. $HURA

Key Points

• BlackRock purchased 690,088 shares of TuHURA Biosciences during the second quarter, valued at approximately $1.6 million and representing about 1.08% of the company.
• Other institutions also increased exposure, including Geode Capital Management, which more than doubled its position. However, institutional investors collectively own only 0.62% of TuHURA’s stock.
• Analyst sentiment is mixed but leans positive: five analysts rate the stock a Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and a $9 target price. Shares opened at $2.14, while the company remains unprofitable and reported a quarterly loss of $0.14 per share.

BlackRock Inc. purchased a new stake in shares of TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 690,088 shares of the company's stock, valued at approximately $1,615,000. BlackRock Inc. owned about 1.08% of TuHURA Biosciences at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Bank of America Corp DE bought a new position in TuHURA Biosciences in the fourth quarter valued at approximately $59,000. Jane Street Group LLC acquired a new stake in TuHURA Biosciences during the 1st quarter worth $69,000. Geode Capital Management LLC raised its position in shares of TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company's stock valued at $1,300,000 after acquiring an additional 307,260 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at $27,000. Finally, New York State Common Retirement Fund acquired a new position in shares of TuHURA Biosciences in the 2nd quarter valued at $97,000. Institutional investors and hedge funds own 0.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Weiss Ratings restated a "sell (e+)" rating on shares of TuHURA Biosciences in a research report on Friday, July 17th. Citizens Jmp restated a "market outperform" rating and set a $9.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, August 18th. Finally, Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a research note on Sunday, May 31st. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

TuHURA Biosciences Stock Performance

NASDAQ HURA opened at $2.14 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18. TuHURA Biosciences, Inc. has a 52 week low of $0.41 and a 52 week high of $3.43. The stock has a market capitalization of $136.38 million, a price-to-earnings ratio of -3.96 and a beta of -0.02. The stock's 50 day moving average price is $2.22 and its two-hundred day moving average price is $2.15.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. As a group, analysts anticipate that TuHURA Biosciences, Inc. will post -0.55 earnings per share for the current fiscal year.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.